筛选条件 共查询到40条结果
排序方式
Safety and Efficacy of Neoadjuvant Immune Checkpoint Inhibitor Therapy in Patients with Resectable Non-small-Cell Lung Cancer: A Systematic Review

期刊: TARGETED ONCOLOGY, 2021; 16 (4)

Background Non-small-cell lung cancer (NSCLC) accounts for most new diagnoses of lung cancer, with high morbidity and mortality worldwide. Immune chec......

The Evolving Landscape of Checkpoint Inhibitor Combination Therapy in the Treatment of Advanced Hepatocellular Carcinoma

期刊: TARGETED ONCOLOGY, 2021; 16 (2)

Hepatocellular carcinoma (HCC) is one of the most common cancers and a main cause of cancer-associated death worldwide. Even with the successful launc......

BRAFV600E Mutations Arising from a Left-Side Primary in Metastatic Colorectal Cancer: Are They a Distinct Subset?

期刊: TARGETED ONCOLOGY, 2021; 16 (2)

Background B-Raf proto-oncogene (BRAF)-V600E mutations (BRAFmt) in colorectal cancer (CRC) predominantly occur in right-side (RS) primaries. In metast......

Clinical Value of EGFR Copy Number Gain Determined by Amplicon-Based Targeted Next Generation Sequencing in Patients with EGFR-Mutated NSCLC

期刊: TARGETED ONCOLOGY, 2021; 16 (2)

Background The clinical relevance of epidermal growth factor receptor (EGFR) copy number gain in patients with EGFR mutated advanced non-small cell lu......

A Randomized Phase I Study of Abemaciclib in Chinese Patients with Advanced and/or Metastatic Cancers

期刊: TARGETED ONCOLOGY, 2021; 16 (2)

Background Abemaciclib, a cyclin-dependent kinase 4 and 6 inhibitor, is approved in combination with endocrine therapy or as monotherapy for hormone r......

Osimertinib Versus Comparator EGFR TKI as First-Line Treatment for EGFR-Mutated Advanced NSCLC: FLAURA China, A Randomized Study

期刊: TARGETED ONCOLOGY, 2021; 16 (2)

Background In the global FLAURA study, first-line osimertinib, a third-generation irreversible tyrosine kinase inhibitor (TKI) of epidermal growth fac......

Tumor Mutation Burden as a Potential Biomarker for PD-1/PD-L1 Inhibition in Advanced Non-small Cell Lung Cancer

期刊: TARGETED ONCOLOGY, 2020; 15 (1)

Background Immunotherapy based on programmed cell death protein 1 (PD-1)/programmed death-ligand 1 (PD-L1) inhibitors has revolutionized the treatment......

Genomic Alterations and MYD88(MUT) Variant Mapping in Patients with Diffuse Large B-Cell Lymphoma and Response to Ibrutinib

期刊: TARGETED ONCOLOGY, 2020; 15 (2)

Background Diffuse large B-cell lymphoma (DLBCL) is a clinically heterogeneous malignancy. Following front-line immunochemotherapy, 30-40% of DLBCL pa......

Chemotherapy Plus EGFR-TKI as First-Line Treatment Provides Better Survival for Advanced EGFR-Positive Lung Adenocarcinoma Patients: Updated Data and Exploratory In Vitro Study

期刊: TARGETED ONCOLOGY, 2020; 15 (2)

Background Previously, we demonstrated that treatment with gefitinib combined with pemetrexed plus carboplatin chemotherapy improved progression-free ......

Heterogeneous Response to First-Generation Tyrosine Kinase Inhibitors in Non-Small-Cell Lung Cancers with Different EGFR Exon 19 Mutations

期刊: TARGETED ONCOLOGY, 2020; 15 (3)

Background Epidermal growth factor receptor (EGFR) exon 19 deletions (19dels) appear in a large number of variants, which has not been distinguished i......

Targeting CD79b for Chimeric Antigen Receptor T-Cell Therapy of B-Cell Lymphomas

期刊: TARGETED ONCOLOGY, 2020; 15 (3)

Background Although chimeric antigen receptor (CAR) T-cell therapy targeting antigens expressed in refractory and relapsed non-Hodgkin B-cell lymphoma......

Clinical Factors Affecting the Response to Osimertinib in Non-Small Cell Lung Cancer Patients with An Acquired Epidermal Growth Factor Receptor T790M Mutation: A Long-Term Survival Analysis

期刊: TARGETED ONCOLOGY, 2020; 15 (3)

Background Osimertinib is a standard therapy for advanced non-small cell lung cancer (NSCLC) patients with an acquired epidermal growth factor recepto......

Dynamics of Plasma EGFR T790M Mutation in Advanced NSCLC: A Multicenter Study

期刊: TARGETED ONCOLOGY, 2019; 14 (6)

BackgroundDroplet digital polymerase chain reaction (ddPCR) is an emerging technology for quantitative cell-free DNA oncology applications. However, a......

JIF:3.68

Development of a Novel EGFR-Targeting Antibody-Drug Conjugate for Pancreatic Cancer Therapy

期刊: TARGETED ONCOLOGY, 2019; 14 (1)

BackgroundOverexpression of epidermal growth factor receptor (EGFR) is common in pancreatic cancer and associated with the poor prognosis of this mali......

JIF:3.68

Serum Alpha1-Globulin as a Novel Prognostic Factor in Metastatic Renal Cell Carcinoma Treated with Tyrosine Kinase Inhibitors

期刊: TARGETED ONCOLOGY, 2019; 14 (2)

Background Serum protein fraction (SPF) is a common parameter reflecting the nutritional and inflammatory status of the human body. However, its role ......

JIF:3.68

共40条页码: 1/3页15条/页